Lime Therapeutics’ Post

Today on the Business of Biotech, molecular biologist-turned-Chief Business Officer Neela Patel and academic-turned-founder of newly-formed Bonum Therapeutics John Mulligan, Ph.D. pull back the curtain on Bonum's transition from its predecessor, Good Therapeutics, Inc., which was fueled by a high-profile asset sale to Roche. Listen in as Neela and John share how the deal got done, how Good turned to Bonum, and where the company's taking its platform next. Listen and subscribe here: https://lnkd.in/edtyEWsF

A tale of perseverance and strategy at 2seventy bio. In just two years, the biotech has weathered layoffs, pipeline reorganizations, fierce competition, FDA safety warnings, and discontinued clinical trials. Yet, CEO Chip Baird credits transparency and a committed staff for keeping the company afloat. Despite the challenges, 2seventy is now on the path to profitability, with Baird predicting reaching that milestone next year. Stay tuned for potential growth strategies once breakeven is achieved. #biotech #perseverance #strategy #celltherapy #CarT #multiplemyeloma #advancedtherapies #regenerativemedicine #lifescience #lifesciences #biotech #biotechnology bluebird bio #milestones #profitability

Meet our founders! 1cBio was founded in 2022 by Jit Chakravarty, Sunny Chen, and Son Pham. Their collaborative journey began almost a decade ago at Medivation, where Jit played a key role in the development and approval of XTANDI® (enzalutamide), while Sunny was part of the team that helped develop TALZENNA®️ (talazoparib). SPARCBIO emerged following Pfizer’s acquisition of Medivation, and as co-workers evolved into first-time entrepreneurs, they fostered a collective synergy in their ability to transform inventions into innovations and build companies with sustainable portfolios. Through countless late-night conference calls, working dinners, and long flights, Jit, Sunny, Son, and their dedicated team developed and supported five unique small-molecule programs. Their efforts resulted in four clinical candidates between 2016 and 2022. In 2019, SPARCBIO's assets were sold in a transaction involving cash and stock, laying the foundation for a new public company (NYSE: NUVB). With an amalgamation of experiences, both personal and professional, the team at 1cBio is driven by their common desire to positively impact patients' lives. These efforts continue to propel the company forward as a clinical-stage enterprise. To learn more visit: www.1cbio.com #FoundingStory #1cBio #Our1cause #DrugDiscovery #DrugDevelopment #BioPharma #Oncology #RareDisease #HPP

I’m excited to share the latest episode of Biotech2050, where I had the pleasure of hosting Jeb Keiper, CEO of Nimbus Therapeutics. In this insightful podcast, we dive deep into Nimbus’ elegant approach to corporate structuring and financing strategy, which has impressively returned over $4B to equity holders. We also discuss the pivotal role of business development in the biotech industry and the art of dealmaking in today’s competitive landscape. Tune in for valuable insights from one of the leading minds in biotech. Link below! #biotech #podcast #drugdevelopment #leadership #clinicaldevelopment #biotechdeals

The latest episode of Biotech2050 is out now, featuring Jeb Keiper, CEO of Nimbus Therapeutics, and hosted by Clora CEO Rahul Chaturvedi. In this episode, Jeb shares his fascinating journey from the labs at MIT and Pfizer to leading Nimbus Therapeutics as CBO and then CEO for nearly a decade. Tune in to gain insights into the unique operating model and financing strategies that have driven Nimbus's success. Jeb also reflects on his many leadership experiences that have shaped him and Nimbus including the importance of taking risks, building a curious team, pioneering a novel deal-making strategy, and fostering a collaborative ecosystem in biotech among CEOs in the last few years - a must-listen for professionals aspiring for executive leadership roles. Check out the new episode using the link below. #biotech #podcast #drugdevelopment #leadership #clinicaldevelopment #biotechdeals

We are excited to announce the successful close of our £40.5 million Series A financing! We are very proud to welcome our new investors Pfizer Ventures LLC, who led the round, COLUMBUS VENTURE PARTNERS,S.G.E.I.C., S.A.U. and British Patient Capital. They were joined by our founding investor Advent Life Sciences, and seed investor Epidarex Capital, underlining strong blue chip confidence behind Curve Therapeutics' vision to transform the lives of patients by addressing disease targets which are intractable to conventional #drugdiscovery methods. The financing will enable Curve Therapeutics to turbocharge its Microcycle® discovery platform and advance its promising pipeline of assets with the potential to treat unmet clinical needs in a diverse range of diseases, including cancer. To learn more about the financing and our proprietary discovery platform, read the full press release here: https://lnkd.in/eRDFP2X6 #biotech #financing #investment

❗𝗪𝗔𝗥𝗡𝗜𝗡𝗚: 2 Discounted Passes Left for the 𝟲𝘁𝗵 𝗠𝗮𝗰𝗿𝗼𝗽𝗵𝗮𝗴𝗲-𝗗𝗶𝗿𝗲𝗰𝘁𝗲𝗱 𝗧𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝗦𝘂𝗺𝗺𝗶𝘁!   Time is running out to be part of the 𝗺𝗼𝘀𝘁 𝗰𝗿𝘂𝗰𝗶𝗮𝗹 𝗲𝘃𝗲𝗻𝘁 𝗶𝗻 𝗺𝗮𝗰𝗿𝗼𝗽𝗵𝗮𝗴𝗲 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀. Don't risk falling behind as top experts 𝗰𝗼𝗻𝗳𝗿𝗼𝗻𝘁 𝘁𝗵𝗲 𝗺𝗼𝘀𝘁 𝗽𝗿𝗲𝘀𝘀𝗶𝗻𝗴 𝗰𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 and share their 𝘀𝗲𝗰𝗿𝗲𝘁𝘀 𝗼𝗻 𝗶𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁𝘀 𝗮𝗻𝗱 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽𝘀.   𝗚𝗿𝗮𝗯 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗽𝗿𝗼𝗴𝗿𝗮𝗺 - https://ter.li/ntamqp   Once these 2 passes are gone, so is your chance to stay ahead in this fast-evolving field.   ⏳ 𝗦𝗮𝘃𝗲 $𝟯𝟬𝟬 𝗯𝘆 𝗺𝗶𝗱𝗻𝗶𝗴𝗵𝘁 𝘁𝗼𝗺𝗼𝗿𝗿𝗼𝘄 - https://ter.li/ook4wg   Don't let this opportunity slip away!   #MacrophageDirectedTherapiesSummit

It's clear that the Annual Meeting is more than just a conference; it's a catalyst for sparking ideas, forming relationships, and advancing progress. As Joe Lewcock, Ph.D., Chief Scientific Officer of Denali Therapeutics, eloquently expressed, "I can see it's been incredibly impactful to be involved, not just through the consortia... but through the relationships we've built at this meeting." Together, we're driving groundbreaking advancements in ALS research. #ALSResearch #EveryoneLives #ALS #EndALS #ALSAwarenessMonth

𝗙𝗼𝗴𝗣𝗵𝗮𝗿𝗺𝗮 𝗯𝗮𝗴𝘀 $𝟭𝟰𝟱𝗠, 𝗮𝗱𝗱𝘀 𝗔𝗹𝗲𝘅𝗶𝘀 𝗕𝗼𝗿𝗶𝘀𝘆 𝘁𝗼 𝘁𝗵𝗲 𝗯𝗼𝗮𝗿𝗱 FogPharma, a biotech from Harvard researcher Greg Verdine that is led by former Johnson & Johnson R&D leader Mathai Mammen, M.D., Ph.D., said it has raised $145 million in a Series E financing. The nine-figure round, biotech’s 13th of 2024, was led by Nextech Invest and included participation from Alex Gorsky, Mammen’s former boss at J&J. The Boston-area biotech is one of a few drug developers to raise that many private rounds before a move to the public markets. The biotech last disclosed a $178 million Series D in November 2022. “I do want to eventually be a public company, but I want to be a really good, solid, robust public company that has multiple milestones that can take hits on failures, which are going to be expected in this industry from time to time, so I don’t want to go out as a fragile company,” Mathai Mammen, M.D., Ph.D. said in an interview with Endpoints News on Jan. 12. “Even if the environment were very conducive to being public right now, I still wouldn’t want to be a public company right now. We’re not in a position to do that,” Mammen continued in the January interview, which came before six biotechs would make the transition to the public markets, including other oncology drugmakers like CG Oncology and ArriVent Biopharma. Nextech designated industry entrepreneur and Curie.Bio co-founder Alexis Borisy to FogPharma’s board, the drug developer also said Friday morning. FogPharma said the funds will go toward the clinical-stage candidate FOG-001, one of the few beta catenin inhibitors to make it into human studies. The candidate is in a Phase I/II in solid tumors. Mammen told Endpoints in January that there were less than a dozen patients in the trial, noting it was still “super-early days.” https://lnkd.in/gKnTEbdt

Calling ALL Drug Hunters - imagine building your next drug discovery program(s) in a company you own and control. #freethefounders Alongside other drug hunters like myself who are there to be your thought partners and help you execute every step of the way. Curie.Bio unlocks an incredible opportunity for founders to build successful therapeutics companies. Founders often suffer from dilution when raising a Series A. Dilution is a product of the capital raised and company valuation. We help founders minimize dilution by maximizing progress with less capital. By reaching critical milestones on blockbuster TPPs, you can raise more capital at a much higher valuation. Last fall, our first portfolio company, Forward Therapeutics, Inc., raised a $50M Series A to generate clinic data! A recent Oppenheimer report revealed this raise was the BIGGEST valuation step up compared to all other therapeutics companies that raised a Series A in the last 12 months. The best part? The founders retained significant ownership in their company. Please don't hesitate to reach out through our website if you have a therapeutic idea worthy of funding. https://lnkd.in/e4NWnqwF